FDA Approves CAPVAXIVE For Children At Risk For Pneumonia, Yet US Distribution Faces Delay

WASHINGTON (dpa-AFX) - Last month the U.S. Food and Drug Administration (FDA) had approved the CAPVAXIVE vaccine for pneumococcal infections in at-risk children aged 2 years or older. However, rec...